Dutogliptin
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Dutogliptin
- Molecular weight
- 241.1
- Structure (SMILES)
- O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O
- dutogliptin
- Dutogliptin
- dutogliptin [INN]
- DUTOGLIPTIN [USAN]
- Dutogliptin [WHO-DD]
- dutogliptin inn
- dutogliptin usan
- dutogliptin who dd
- dutogliptina
- Dutogliptina
- dutogliptine
- Dutogliptine
- phx 1149
- PHX-1149
- phx1149
- Phx1149
- PHX1149
- CAS registry numbers
- 852329-66-9
- ChEMBL ID
- CHEMBL4296719
- InChIKey
- DVJAMEIQRSHVKC-BDAKNGLRSA-N
- PubChem compound IDs
- 11253490
- FDA ingredient codes (UNII)
- 38EAO245ZX
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -gliptin
Mechanisms of action
- Mechanism
- Dipeptidyl peptidase IV inhibitor
- Action type
- Inhibitor
- Target
- Dipeptidyl peptidase 4
- Protein identifier
- P27487
Open Targets mechanisms
- Mechanism
- Dipeptidyl peptidase IV inhibitor
- Action type
- Inhibitor
- Target
- Dipeptidyl peptidase 4
- Condition
- ST Elevation Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0008585
- Subject identifier
- D000072657
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0008585
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008585
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 3
- NCT00530881
- NCT00850239
- NCT00865592
- NCT00947557
- NCT00970424
- NCT00998686
- NCT01089790
- NCT01101945
- NCT05881382
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 17
- Molecular formula
- C10H20BN3O3
- Monoisotopic mass
- 241.1597717
- Natural product
- Yes
- Recorded assays
- 7
- Active assays
- 6
Active assay types
- Confirmatory
Related records
Trials (10)
- Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
- Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
- Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
- Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus
- Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
- Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone
- Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
- Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
- Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
- Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
In development for (4)
- Heart failure Phase 3
- Myocardial infarction Phase 3
- ST-elevation myocardial infarction Phase 3
- Type 2 diabetes mellitus Phase 3
Targets (1)
- DPP4 Dipeptidyl peptidase IV inhibitor